Magrolimab
The first 'don't eat me' signal blocker. Gilead paid $4.9B for it; it was stopped in 2024 after trials showed more deaths, not fewer.
Magrolimab blocks CD47 so macrophages can phagocytose tumour cells. Early single-arm data with azacitidine in TP53-mutant AML and MDS were striking. ENHANCE (higher-risk MDS) was stopped for futility in 2023; ENHANCE-2 (TP53-mutant AML) and ENHANCE-3 (unfit AML) were halted in 2024 after an increased risk of death in the magrolimab arms; the FDA placed a full clinical hold. Gilead had acquired Forty Seven for $4.9B in 2020.
Lesson: a ubiquitous target (CD47 is on every red cell) plus an immunosuppressed population is a narrow window; single-arm response rates in TP53-mutant disease were not predictive of survival.
No public structure of magrolimab; representative IgG shown.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Magrolimab" OR ABSTRACT:"Magrolimab" OR TITLE:"Hu5F9-G4" OR ABSTRACT:"Hu5F9-G4" OR TITLE:"GS-4721" OR ABSTRACT:"GS-4721") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Magrolimab, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductTrastuzumab duocarmazine
Shares Failures are hidden and the tags failure, lesson:toxicity.
- ProductEpacadostat
Shares Public post-mortem reports when a cancer drug programme is stopped, Failures are hidden, Cold tumours and the immunosuppressive microenvironment and the tag failure.
- ProductRovalpituzumab tesirine
Shares Public post-mortem reports when a cancer drug programme is stopped, Failures are hidden and the tag failure.
- ProductTiragolumab
Shares Automatic offer of shelved cancer assets to non-profits after two years, Failures are hidden, Cold tumours and the immunosuppressive microenvironment and the tag failure.
- ProductEprenetapopt
Shares Failures are hidden, Acute myeloid leukaemia and the tag failure.
- ProductMelphalan flufenamide
Shares Failures are hidden and the tag failure.
- ProductTusamitamab ravtansine
Shares Failures are hidden and the tag failure.
- ProductBempegaldesleukin
Shares Failures are hidden and the tag failure.